22nd Century Group Inc. (XXII)
NASDAQ (CM) NASDAQ (CM) Primary Summary
22nd Century Group, Inc. (XXII) Q3 2025 Earnings Call Transcript
22nd Century Group, Inc. ( XXII ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Matthew Kreps - Investor Relations Lawrence Firestone - President & CEO Daniel Otto - CFO & Principal Accounting Officer Conference Call Participants Andrew White Presentation Operator Welcome to 22nd Century Group's Third Quarter 2025 Conference Call and Webcast. [Operator Instructions] It is now my pleasure to turn the floor over to Matt Kreps, Investor Relations for 22nd Century Group.
22nd Century Group, Inc. (XXII) Q2 2025 Earnings Call Transcript
22nd Century Group, Inc. (NASDAQ:XXII ) Q2 2025 Earnings Conference Call August 14, 2025 8:00 AM ET Company Participants Daniel A. Otto - CFO & Principal Accounting Officer Lawrence D.
22nd Century Group, Inc. (XXII) Q1 2025 Earnings Call Transcript
22nd Century Group, Inc. (NASDAQ:XXII ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Matt Kreps - IR Larry Firestone - CEO Dan Otto - CFO Conference Call Participants Andrew White - Emerging Growth Research Operator Welcome to 22nd Century Group's First Quarter 2025 Conference Call and Webcast. At this time, all participants have been placed in a listen-only mode.
22nd Century Group Inc. (XXII) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has 22nd Century Group Inc. ever had a stock split?
22nd Century Group Inc. Profile
| Tobacco Industry | Consumer Staples Sector | Lawrence D. Firestone CEO | NASDAQ (CM) Exchange | 90137F509 CUSIP |
| US Country | 56 Employees | - Last Dividend | 20 Jun 2025 Last Split | 26 Jan 2011 IPO Date |
Overview
22nd Century Group, Inc. is a pioneering company in the field of agricultural biotechnology, concentrating its efforts on tobacco harm reduction and the advancement of health and wellness through innovative plant science. This involves the development of reduced nicotine tobacco products and leveraging plant biotechnology for life science and consumer product advancements. Founded in 1998 and based in Buffalo, New York, the company engages in scientific research to achieve its objectives, including collaborations aimed at enhancing the properties of hemp and cannabis for both medical and agricultural applications.
Products and Services
- VLN King & VLN Menthol King Cigarettes: These products represent the company’s forefront innovation, characterized by their very low nicotine content. Tailored to address the public health concern regarding nicotine addiction, these cigarettes aim at providing a safer alternative for smokers. The VLN King and VLN Menthol King are designed not only to reduce smokers' nicotine consumption but also to potentially aid in smoking cessation efforts.
- SPECTRUM Research Cigarettes: Specially developed for use in independent clinical studies, SPECTRUM research cigarettes serve an important role in tobacco research. They are utilized by scientists and health professionals to investigate the impact of nicotine and other tobacco product constituents on health, behavior, and genetics. By providing a controlled product for clinical research, 22nd Century Group, Inc. significantly contributes to advances in public health knowledge regarding tobacco use.
- Hemp/Cannabis Plant Development: In collaboration with Keygene N.V., 22nd Century Group, Inc. is also making strides in the development of hemp and cannabis plants with enhanced cannabinoid profiles and agronomic traits. This initiative aims to leverage plant biotechnology for medical, therapeutic, and agricultural purposes, offering potentially revolutionary applications in these fields. The effort underscores the company’s commitment to utilizing advanced biotechnologies to improve the quality and functionality of plant-derived products.
